DPP-4 inhibitors have neutral effects on cardiovascular outcomes in T2DM with no evidence for additional benefits of clinical relevance in NAFLD, although adequately powered, controlled studies with primary histological endpoints are lacking (21, 22). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.